Sep 2026· Advancement of science· 0 citations· 63 references
Medicine
TL;DR
Findings suggest that MSN‐BO@LUT not only provides a developed, safe, effective nanotherapeutic strategy for SCI treatment but also serves as a translatable template for developing precision nanomedicines targeting CNS disorders.
Abstract
ABSTRACT Spinal cord injury (SCI) is a devastating disorder of the central nervous system (CNS) leading to irreversible neurological deficits. Effective pharmacotherapy remains elusive, due to the restrictive blood‐spinal cord barrier (BSCB), underscoring the urgent need for targeted and efficient drug delivery strategies. Luteolin (LUT), a natural flavonoid with potent anti‐neuroinflammatory properties, presents a promising therapeutic option; however, it is compromised by poor solubility, low bioavailability, and limited BSCB penetration. Drawing inspiration from the traditional Chinese medicine concept of the “orifice‐opening” effect of borneol (BO), we developed BO‐modified mesoporous silica nanoparticles (MSN‐BO@LUT) for targeted LUT delivery to the spinal cord. MSN‐BO@LUT significantly enhanced LUT delivery to the spinal cord, achieving a 286.36‐fold increase over LUT, and maintained a concentration of 802.17 ng/mL at 24 h. MSN‐BO@LUT demonstrated robust anti‐neuroinflammatory and neuroprotective effects in SCI mice, reducing microglial infiltration, promoting functional recovery, and showing favorable efficacy and safety compared with the positive control methylprednisolone. Mechanistically, released LUT targets protein arginine N‐methyltransferase, reduces toll‐like receptor 4 methylation, and inhibits nuclear factor kappa B‐mediated pro‐inflammatory signaling, thereby suppressing microglial M1 polarization. These findings suggest that MSN‐BO@LUT not only provides a developed, safe, effective nanotherapeutic strategy for SCI treatment but also serves as a translatable template for developing precision nanomedicines targeting CNS disorders.
A RVG‐modified liposomal nanoplatform for targeted delivery of mollugin (Mol@Lip‐RVG) as a novel therapeutic strategy for SCI resulted in enhanced neuro‐preservation and substantial improvement in motor function recovery, achieved through dual modulation of microglial reprogramming and attenuation of oxidative stress.
Quan Zhou, I. Shaikh, Jian-Feng Wang et al.· Advanced Healthcare Material...· 0 citations
The secondary injury cascade following spinal cord injury (SCI) involves complex pathological processes, with the interplay between ferroptosis and oxidative stress serving as a key impediment to neural repair. Ferrostatin-1 (Fer-1), an inhibitor of ferroptosis, faces limitations in clinical translation due to its low...
Traumatic brain injury (TBI) is a highly heterogeneous neurological condition with extremely high rates of mortality and disability. Currently, the clinical management of TBI relies primarily on palliative care, whereas complex secondary injury cascades limit the ability of traditional single‐target drugs to achieve...
Jue Zhu, Wei-Quan Liao, Zi-Qin Lian et al.· Med Research· 0 citations
Spinal cord injury (SCI) triggers a complex secondary injury cascade characterized by oligodendrocyte (OL) death and axonal demyelination, leading to permanent neurological deficits. Despite the presence of endogenous oligodendrocyte progenitor cells (OPCs), the inhibitory microenvironment-marked by inflammation, glial...
E. Petillo, V. Veneruso, E. Frigerio et al.· Advances in Materials· 0 citations
Ischemic stroke reperfusion injury is driven by oxidative stress and neuroinflammation, but current neuroprotective strategies suffer from poor targeting, limited functionality, and low blood‑‐brain barrier (BBB) penetration. Herein, a multifunctional nanoplatform (RM@HPAN) is constructed: a hollow mesoporous Prussian...
A new machine-learning framework aims to improve the success rate of computational protein design while moving away from results that reproduce sequences found in nature.